WO2002087497A3 - Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use - Google Patents

Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use Download PDF

Info

Publication number
WO2002087497A3
WO2002087497A3 PCT/US2002/012502 US0212502W WO02087497A3 WO 2002087497 A3 WO2002087497 A3 WO 2002087497A3 US 0212502 W US0212502 W US 0212502W WO 02087497 A3 WO02087497 A3 WO 02087497A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agent
synthesis
methods
ligand conjugate
conjugate compositions
Prior art date
Application number
PCT/US2002/012502
Other languages
French (fr)
Other versions
WO2002087497A2 (en
Inventor
Chun Li
Javier O Vega
Shi Ke
Sidney Wallace
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Priority to EP02728872A priority Critical patent/EP1610751A4/en
Priority to CA002444383A priority patent/CA2444383A1/en
Priority to PCT/US2002/012502 priority patent/WO2002087497A2/en
Publication of WO2002087497A2 publication Critical patent/WO2002087497A2/en
Publication of WO2002087497A3 publication Critical patent/WO2002087497A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/103—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against receptors for growth factors or receptors for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Conjugate molecules comprising a ligand or targeting moiety bonded to a polymer spacer, a polymer carrier bonded to the polymer spacer, and a therapeutic agent bound to the polymer carrier (with or without a linker) are disclosed. The conjugate molecules are useful for the selective delivery of therapeutic agents to tumors or other tissues expressing biological receptors.
PCT/US2002/012502 2001-04-26 2002-04-19 Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use WO2002087497A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02728872A EP1610751A4 (en) 2001-04-26 2002-04-19 Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
CA002444383A CA2444383A1 (en) 2001-04-26 2002-04-19 Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
PCT/US2002/012502 WO2002087497A2 (en) 2001-04-26 2002-04-19 Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US28645301P 2001-04-26 2001-04-26
US60/286,453 2001-04-26
US33496901P 2001-12-04 2001-12-04
US60/334,969 2001-12-04
US34314701P 2001-12-20 2001-12-20
US60/343,147 2001-12-20
PCT/US2002/012502 WO2002087497A2 (en) 2001-04-26 2002-04-19 Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use

Publications (2)

Publication Number Publication Date
WO2002087497A2 WO2002087497A2 (en) 2002-11-07
WO2002087497A3 true WO2002087497A3 (en) 2009-07-16

Family

ID=27485958

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/012502 WO2002087497A2 (en) 2001-04-26 2002-04-19 Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use

Country Status (1)

Country Link
WO (1) WO2002087497A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635680B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
US7645739B2 (en) 2001-02-21 2010-01-12 Alavita Pharmaceuticals, Inc. Modified annexin compositions and methods of using same
US7635676B2 (en) 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
KR20070108953A (en) 2003-04-22 2007-11-13 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. Peptide vectores
US7615221B2 (en) * 2004-07-23 2009-11-10 Oncologic, Inc. Compositions and methods for treating cancer
EP2206736B1 (en) 2005-12-05 2012-02-08 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
WO2007122259A1 (en) * 2006-04-25 2007-11-01 Centre National De La Recherche Scientifique (Cnrs) Functionalization of gold nanoparticles with oriented proteins. application to the high-density labelling of cell membranes
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
RU2487877C2 (en) 2008-04-30 2013-07-20 Иммьюноджен, Инк. Potent conjugates and hydrophilic cross-linking agents (linkers)
ES2432152T3 (en) 2008-07-29 2013-12-02 Nanocarrier Co., Ltd. Polymeric micella of active addressing type that carries drug contained in it and medicinal composition
EP2850201A4 (en) * 2012-05-11 2016-08-31 Alexander Krantz Site-specific labeling and targeted delivery of proteins for the treatment of cancer
ES2701076T3 (en) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Hydrophilic linkers and their uses for the conjugation of drugs to molecules that bind to cells
CA2945945C (en) * 2014-04-15 2023-10-03 The Regents Of The University Of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
US20180016352A1 (en) * 2015-02-05 2018-01-18 The University Of Queensland Targeting constructs for delivery of payloads
EP3428147A4 (en) * 2016-03-07 2019-08-28 Hanmi Pharm. Co., Ltd. Polyethylene glycol derivative and use thereof
CN114306340B (en) * 2021-12-14 2023-03-07 山东大学 Preparation method and application of cholic acid-quaternized chitosan oligosaccharide-ES 2 peptide/camptothecin conjugate
CN115501346B (en) * 2022-09-28 2024-04-23 安徽农业大学 Tea dreg protein-epsilon-polylysine nano material and anthocyanin nano compound and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5412072A (en) * 1989-05-11 1995-05-02 Research Development Corp. Of Japan Water soluble high molecular weight polymerized drug preparation
US5635603A (en) * 1993-12-08 1997-06-03 Immunomedics, Inc. Preparation and use of immunoconjugates
US6251866B1 (en) * 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5412072A (en) * 1989-05-11 1995-05-02 Research Development Corp. Of Japan Water soluble high molecular weight polymerized drug preparation
US5635603A (en) * 1993-12-08 1997-06-03 Immunomedics, Inc. Preparation and use of immunoconjugates
US6251866B1 (en) * 1997-08-05 2001-06-26 Watson Laboratories, Inc. Conjugates targeted to the interleukin-2 receptor

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BLAIR ET AL.: "Linkage of cytotoxic agents to immunoglobulins", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 59, 1983, pages 129 - 143, XP000646723 *
DATABASE MEDLINE [online] INTERNATIONAL (COLUMBUS, OH, USA); BENNIS ET AL.: "Tailoring new gene delivery designs for specific targets", XP002968594, accession no. STN Database accession no. 200222278 *
GREENFIELD ET AL.: "In vitro evaluation of immunoconjugates prepared by linking mitomycin C to monoclonal antibodies via polyglutamic acid carriers", ANTIBODY, IMMUNOCONJUGATES AND RADIOPHARMACEUTICALS, vol. 2, no. 3, 1989, pages 201 - 216, XP002968595 *
JOURNAL OF DRUG TARGETING, vol. 8, no. 1, 2000, pages 1 - 12 *
See also references of EP1610751A4 *

Also Published As

Publication number Publication date
WO2002087497A2 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
WO2002087497A3 (en) Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
WO2002087498A3 (en) Diagnostic imaging compositions, their methods of synthesis and use
WO2004110358A3 (en) Polymeric conjugates for tissue activated drug delivery
WO2001082899A3 (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
EP2353611A3 (en) Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
AU2003224644A1 (en) Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
ATE365562T1 (en) TARGETED COMBINATION IMMUNOTHERAPY FOR CANCER
WO2005081711A3 (en) Monomethylvaline compounds capable of conjugation to ligands
WO2007018431A3 (en) Triazole-containing releasable linkers and conjugates comprising the same
WO2009016516A8 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
WO2002100336A3 (en) Tissue-specific endothelial membrane proteins
CA2413190A1 (en) Methods for treating rheumatic diseases using a soluble ctla4 molecule
WO2008076333A3 (en) Polymer-drug conjugates with tether groups for controlled drug delivery
WO2000064486A3 (en) Enzymatically activated polymeric drug conjugates
WO2008073162A3 (en) Lysine acetylation sites
EP2230254A3 (en) Anti-IGFR1 antibody therapeutic combinations
WO2005023294A3 (en) Polyacetal drug conjugates as release system
AU2002326610A1 (en) Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
WO2007011968A3 (en) Beta-glucuronide-linker drug conjugates
WO2007019478A3 (en) Drug delivery from implants using self-assembled monolayers - therapeutic sams
AU8366398A (en) Trifunctional reagent for conjugation to a biomolecule
WO2003035011A3 (en) Multidrug multiligand conjugates for targeted drug delivery
AU2002215904A1 (en) Compounds with a branched linker
AU2003283228A1 (en) Shiga toxin b-subunit as a vector for tumor diagnosis and drug delivery to gb3 expressing tumors
WO2008021542A3 (en) Lysine acteylation sites

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2444383

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2002258895

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002728872

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2002728872

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2002728872

Country of ref document: EP